SCHEMBL19458796

SCHEMBL19458796

CC1(C)CC(CCN2CCC(c3ccccc3)CC2)OC1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 15/20 1.00
DRD2 P14416 1/20 0.51
CARM1 Q86X55 1/20 0.48
PRMT6 Q96LA8 1/20 0.48
SLC18A3 Q16572 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17592848 1.00 HTR7 (1.00) HTR7DRD2CARM1PRMT6SLC18A3
SCHEMBL17592912 1.00 HTR7 (1.00) HTR7DRD2CARM1PRMT6SLC18A3
Trifluoroacetic Acid SCHEMBL18227620 0.92 HTR7 (0.84) HTR7DRD2SLC18A3
SCHEMBL22219714 0.87 HTR7 (0.76) HTR7DRD2
SCHEMBL22219749 0.87 HTR7 (0.76) HTR7DRD2
SCHEMBL20465846 0.86 HTR7 (0.76) HTR7DRD2
SCHEMBL20465845 0.86 HTR7 (0.76) HTR7DRD2
SCHEMBL16150495 0.86 HTR7 (0.75) HTR7
SCHEMBL22219778 0.85 HTR7 (0.73) HTR7DRD2
SCHEMBL22219753 0.85 HTR7 (0.73) HTR7DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180221365-A1 NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2018-08-09 US claimed
US-20170298037-A1 Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-10-19 US claimed
EP-3200589-B1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE UNIV TEMPLE (US) 2026-03-11 EP disclosed
US-12269809-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-04-08 US disclosed
US-20220306596-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-09-29 US disclosed
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-05-05 US disclosed
US-11192871-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-12-07 US disclosed
US-20200223810-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-07-16 US disclosed
US-10544117-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use Temple University—Of the Commonwealth System of Higher Education (US) 2020-01-28 US disclosed
US-20180221365-A1 NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2018-08-09 US disclosed
US-20170298037-A1 Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192871-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 HTR7 1/4885DRD2 261/4885CARM1 3438/4885
US-20180221365-A1 NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 HTR7 83/4885DRD2 209/4885CARM1 4409/4885
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 HTR7 68/4885DRD2 273/4885CARM1 4016/4885
US-20170298037-A1 Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use HTR7, HTR6, HTR5A HTR7 1/4885DRD2 328/4885CARM1 3996/4885
US-20200223810-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE HTR7, HTR6, HTR5A HTR7 1/4885DRD2 328/4885CARM1 3996/4885
US-10544117-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 HTR7 1/4885DRD2 295/4885CARM1 3694/4885
US-20220306596-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE HTR7, HTR6, HTR5A HTR7 1/4885DRD2 328/4885CARM1 3996/4885
US-12269809-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 HTR7 1/4885DRD2 261/4885CARM1 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.